Author of

• 20039

  +

  Poster Display Session (ID 63)

  • Event: ELCC 2017
  • Type: Poster Display Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1

  • 19865

    +

    109P - Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors (ID 322)

    12:30 - 13:00  |  Author(s): L. Dai
    • Abstract

    Background:
    The study aimed to explore the efficacy of sequential administration of EGFR TKI and pemetrexed doublet chemotherapy (P), two effective therapies, in advanced NSCLC patients with EGFR mutant tumors.
    
    Methods:
    This was a retrospective study where patients prescribed with EGFR-TKI (gefitinib or icotinib) from Jan 2013 to Jan 2016 were screened. Patients must have metastastic diseases harboring TKI-sensitizing EGFR mutation. They must be older than 18 years, and have evaluable target lesions. Whether TKI or P was used in the first line, it must be switched to the other in the second line. PFS in both first line (PFS1) and second line (PFS2) was collected.
    
    Results:
    We screened totally 550 patients (gefitinib n = 455, icotinib n = 95) to enroll a cohort of 37 patients. However, 1 patient was found to subject adjuvant TKI therapy and therefore was excluded. They were all adenocarcinoma except 1 adenosquamous carcinoma. Gender, good PS, mutation type were equally distributed (male n = 19 vs female n = 17, PS:0 n = 21 vs PS:1 n = 15, exon 19 del n = 14 vs L858R n = 14 vs other type n = 8). The median age was 50.5 years. For the whole cohort, the total PFS (PFS1+PFS2) was 18.1 m (95%CI: 15.2-21.1 m). For the patients receiving first-line TKI, PFS1 and PFS2 were 10.3 m and 6.6 m. And for those receiving first-line P, PFS1 and PFS2 were 3.4 m and 11.5 m.
    
    Conclusions:
    Our results argued the sequential usage of TKI and P achieve a long period of response in advanced NSCLC patients with EGFR-mutant tumors, comparable to that of synchronous administration (15.4 m, JMIT study).
    
    Clinical trial identification:
    NA
    
    Legal entity responsible for the study:
    West China Hospital, Sichuan University
    
    Funding:
    West China Hospital, Sichuan University
    
    Disclosure:
    All authors have declared no conflicts of interest.